Please login to the form below

Not currently logged in
Email:
Password:

Genesis Biopharma names Hans Bishop as chair

Former chief operating officer of Dendreon joins specialist in cancer immunotherapies

Former chief operating officer of Dendreon Hans Bishop has been appointed executive chair of the board at Genesis Biopharma.

The US biotech specialises in cancer immunotherapies and Bishop first joined Genesis as a director in the beginning of 2012.

He will take over from Anthony Cataldo who will remain at the firm as a director.

“To support our business plan we have been expanding our leadership with talented, experienced professionals,” said Cataldo.

“The addition of Hans as our executive chair further enhances this dynamic team as he is a proven leader with an impressive track record of enhancing operational and financial results.”

Prior to his role at Dendreon, Bishop served as president of Bayer's speciality medicine business division from 2006 until 2009, leading units in oncology, neurology, ophthalmology and haematology.

From 2004 to 2006 he held the position of senior VP, global commercial operations for Chiron Corporation, now part of Novartis.

Commenting on his appointment, Bishop said: “It is a privilege to serve as executive chair of Genesis Biopharma at this important point in the company's evolution.  I look forward to building a strong leadership team & working with my colleagues on the board to steer the company to success.”

30th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics